Understanding APOL1-Mediated Kidney Disease (AMKD): Causes, Symptoms, and Emerging Research

The Rare360 Editorial Team
19 hours ago
8 min read

A doctor explaining about AMKD to a patient.

Chronic kidney disease affects an estimated 850 million people worldwide and remains one of the leading causes of poor health outcomes and premature death globally. More than 1 in 7 U.S. adults live with chronic kidney disease, many without even realizing it. While conditions such as diabetes and high blood pressure are widely recognized contributors to kidney damage, researchers are increasingly uncovering the important role genetics can play in kidney health. One genetic condition gaining growing attention in nephrology research is APOL1-mediated kidney disease (AMKD), a term increasingly used to describe kidney diseases associated with high-risk APOL1 gene variants.

For many patients and families, the journey to understanding kidney disease can feel overwhelming, especially when genetic risk factors are involved. Researchers now know that certain APOL1 gene variants can increase the risk of developing progressive kidney disease. However, not everyone who carries these variants will develop kidney disease, highlighting the complex interaction between genetics, environment, and other health factors.

As genetic testing and kidney research continue to advance, healthcare professionals are gaining deeper insight into how APOL1 variants contribute to kidney damage, disease progression, and disparities in kidney health outcomes. Greater awareness of AMKD may help support earlier diagnosis, improved monitoring, and more personalized approaches to care for individuals at risk.

What Is APOL1-Mediated Kidney Disease (AMKD)?

The APOL1 gene is part of the body’s natural immune defense system and helps protect against certain harmful parasites and infections. Scientists first became interested in this gene after discovering that specific APOL1 variants provided protection against African sleeping sickness, a dangerous parasitic disease historically found in parts of sub-Saharan Africa. While these genetic variants may have offered an important survival advantage generations ago, researchers later uncovered an unexpected connection between APOL1 and kidney disease.

Two APOL1 variants, known as G1 and G2, are now strongly associated with an increased risk of several serious kidney conditions. Individuals who inherit two APOL1 risk variants, one from each parent, are considered to have what is often referred to as a “high-risk genotype.” Studies have shown that people with two APOL1 risk variants may face a significantly greater risk of developing chronic kidney disease (CKD), focal segmental glomerulosclerosis (FSGS), and kidney failure compared to individuals without these variants.

However, genetics alone does not tell the whole story. Having APOL1 risk variants does not guarantee someone will develop kidney disease, which has led researchers to investigate why some individuals remain healthy while others experience progressive kidney damage. Scientists now believe that additional factors, sometimes called “second hits,” help to trigger disease development. These factors may include viral infections, chronic inflammation, diet, high blood pressure, environmental exposures, or other underlying health conditions.

Although research is still ongoing, experts believe that abnormal APOL1 protein activity may directly damage specialized kidney cells called podocytes. These cells play a critical role in filtering waste and excess fluids from the blood while preventing important proteins from leaking into the urine. When podocytes become injured, the kidneys may gradually lose their ability to function properly. Over time, this can lead to inflammation, scarring within the kidneys, protein leakage, and progressive loss of kidney function.

Symptoms of APOL1-Mediated Kidney Disease (AMKD)

One of the challenges with APOL1-mediated kidney disease (AMKD) is that symptoms often develop gradually and may go unnoticed in the early stages. Many individuals do not realize something is wrong until routine bloodwork or urine testing reveals signs of kidney damage. In some cases, people may feel completely healthy while kidney function slowly declines over time.

As the disease progresses, symptoms can become more noticeable and may begin to affect daily life. As kidney damage progresses, symptoms may include:

Protein in the urine (proteinuria)
Foamy or bubbly urine
Swelling in the legs, ankles, feet, hands, or around the eyes
High blood pressure
Fatigue and weakness
Difficulty concentrating or “brain fog”
Reduced appetite
Muscle cramps
Trouble sleeping
Shortness of breath, especially in advanced kidney disease
Nausea in more advanced stages

Because symptoms can overlap with many other kidney disorders, diagnosis may be delayed.

Challenges in Diagnosing APOL1-Mediated Kidney Disease (AMKD)

Diagnosing APOL1-mediated kidney disease (AMKD) can be difficult because symptoms often develop slowly and may not appear until kidney damage has already progressed. Many symptoms associated with AMKD, including fatigue, swelling, high blood pressure, and protein in the urine, are also common in other kidney and chronic health conditions, which can sometimes delay diagnosis.

To evaluate kidney health, healthcare providers typically use a combination of tests and medical evaluations, including blood and urine testing, blood pressure monitoring, imaging studies, family history assessment, and, in some cases, kidney biopsy or genetic testing for APOL1 risk variants.

Genetic testing can help explain inherited kidney disease risk, especially in individuals with unexplained kidney dysfunction or a family history of kidney disease. However, testing may also raise emotional, financial, and ethical concerns, including questions about privacy, insurance coverage, and the potential impact on family members.

Awareness of APOL1-mediated kidney disease is still growing within the medical community, and access to specialized care or genetic counselling may vary depending on location and healthcare resources. Researchers hope that greater awareness, earlier screening, and expanded access to testing and counselling will help improve diagnosis and personalized care for individuals at risk.

Who Should Consider APOL1 Genetic Testing?

APOL1 genetic testing is not routinely recommended for everyone, but it may be helpful for certain individuals who have a higher likelihood of inherited kidney disease risk. Testing may help provide additional insight into unexplained kidney problems, support earlier monitoring, and guide conversations with healthcare providers about long-term kidney health.

Individuals who may consider discussing APOL1 testing with a healthcare professional include:

People with chronic kidney disease (CKD) without a clear cause
Individuals diagnosed with focal segmental glomerulosclerosis (FSGS) or other unexplained kidney disorders
People with a family history of kidney disease, kidney failure, or dialysis
Individuals with recent West or sub-Saharan African ancestry and signs of kidney dysfunction
Younger individuals who develop high blood pressure or kidney disease earlier than expected
Potential living kidney donors who may wish to better understand their genetic kidney health risk
Individuals with persistent protein in the urine (proteinuria) or declining kidney function without a known explanation

Because genetic testing can carry emotional, medical, and personal implications, many experts recommend genetic counselling before and after testing whenever possible. A healthcare provider or genetic counsellor can help explain what APOL1 test results may, and may not, mean for an individual’s future health, family members, and treatment decisions.

Importantly, having APOL1 high-risk variants does not guarantee that someone will develop kidney disease. Many people with these variants never experience kidney problems, while others may develop progressive disease due to a combination of genetic, environmental, and other health-related factors.

Learn More
Research is being conducted in order to gain a better understanding as to how AMKD impacts people's lives. If you or a loved one is suspected to have or has been diagnosed with AMKD, you have the opportunity to include your perspectives, insights and experiences (P.I.E.) by subscribing to the Rare360 P.I.E. Program.

Current Treatment Approaches for APOL1-Mediated Kidney Disease (AMKD)

Although there is currently no cure specifically for APOL1-mediated kidney disease (AMKD), significant progress has been made in understanding how to slow kidney damage, manage symptoms, and improve long-term outcomes. Treatment today primarily focuses on protecting kidney function, reducing complications, and addressing the underlying factors that may worsen disease progression.

Because APOL1-mediated kidney disease can progress differently from person to person, treatment plans are often individualized based on kidney function, blood pressure levels, proteinuria, and other overall health conditions.

Blood Pressure Management

Controlling blood pressure remains one of the most important ways to protect kidney health and slow disease progression. High blood pressure can place additional stress on already damaged kidneys, accelerating the decline in kidney function over time.

Healthcare providers commonly prescribe medications such as:

Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin receptor blockers (ARBs)

These medications are designed to lower blood pressure but may also reduce protein leakage into the urine (proteinuria), which is a major marker of kidney damage.

Regular blood pressure monitoring and early treatment can help identify complications earlier.

Kidney-Protective Therapies

In recent years, newer kidney-protective medications have changed the landscape of chronic kidney disease treatment. Certain therapies originally developed for diabetes management are now being used more broadly to help slow kidney disease progression, even in some individuals without diabetes.

Although research specifically focused on APOL1-mediated disease is still evolving, SGLT2 inhibitors have demonstrated kidney-protective benefits across many forms of chronic kidney disease. Healthcare professionals may also recommend medications and treatment strategies aimed at:

Reducing inflammation
Managing cholesterol levels
Controlling blood sugar
Protecting cardiovascular health
Preventing further kidney stress

Lifestyle and Dietary Changes

Lifestyle modifications can play an important role in supporting kidney health and improving overall well-being. While lifestyle changes cannot reverse genetic risk, they may help reduce additional strain on the kidneys and support overall kidney health.

Patients may be encouraged to:

Limit sodium (table salt) intake
Stay physically active
Maintain a healthy weight
Avoid smoking and tobacco use
Stay hydrated appropriately
Manage diabetes and cardiovascular risk factors
Limit alcohol consumption
Attend regular medical follow-up appointments

In some cases, healthcare providers or renal dietitians may recommend individualized dietary adjustments based on kidney function, potassium levels, or protein intake.

Dialysis and Kidney Transplantation

For individuals with advanced kidney failure, dialysis or kidney transplantation may eventually become necessary. Dialysis helps remove waste products and excess fluids from the blood when the kidneys can no longer function adequately.

Kidney transplantation often offers improved quality of life and survival for eligible patients with end-stage kidney disease. However, researchers are continuing to study how APOL1 risk variants may influence transplant outcomes, particularly when high-risk APOL1 variants are present in kidney donors or recipients.

Precision Medicine and Genetic Research

Advances in genetic testing and precision medicine are also helping researchers better identify individuals at increased risk of kidney disease progression. Scientists hope that personalized treatment strategies based on genetic risk profiles may eventually improve outcomes and allow earlier intervention.

Emerging APOL1-Targeted Therapies

Researchers are actively developing therapies designed specifically to target APOL1-related kidney damage. One investigational medication is inaxaplin (formerly VX-147), an oral therapy developed to reduce harmful APOL1 protein activity within kidney cells. Early clinical studies have shown encouraging results, including reductions in proteinuria among some patients with APOL1-associated kidney disease.

In addition to inaxaplin, scientists continue to study other targeted APOL1 therapies aimed at slowing kidney damage, protecting podocytes, and improving long-term kidney outcomes. While many of these treatments are still undergoing clinical trials and regulatory review, they represent an important step toward more personalized therapies for individuals living with APOL1-mediated kidney disease.

The Importance of Awareness, Advocacy, and Hope for the Future

Awareness of APOL1-mediated kidney disease (AMKD) continues to grow, but many people are still unfamiliar with the condition and the role genetics can play in kidney health. Earlier recognition of symptoms, family history, and genetic risk factors may help support earlier diagnosis and more proactive kidney care.

Advocacy organizations, researchers, healthcare providers, and patient communities are working to improve awareness, expand access to genetic counselling and specialized care, address healthcare disparities, and support research into new therapies. Open conversations between patients, families, and healthcare professionals can also help individuals make more informed decisions about their health.

At the same time, advances in genetics, precision medicine, and APOL1-targeted therapies are offering renewed hope for the future. Researchers continue to study why some individuals develop progressive kidney disease while others do not, with the goal of developing more personalized and effective treatment options. Continued research, increased awareness, and equitable access to care may help improve outcomes and quality of life for individuals and families affected by APOL1-mediated kidney disease. As research continues to advance, growing awareness and earlier intervention may help improve outcomes for individuals and families affected by APOL1-mediated kidney disease.

References: